Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 2:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 27 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Fluticasone Propionate/Formoterol Fumarate Clear all
Completed Phase 4 Interventional Results available

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT03478696
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
budesonide/formoterol, albuterol/salbutamol, FF/UMEC/VI, Placebo to match budesonide/formoterol, tiotropium, Placebo to match FF/UMEC/VI, placebo to match tiotropium, ELLIPTA, MDI, HandiHaler
Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
732 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
42
States / cities
Mobile, Alabama • Bakersfield, California • Sacramento, California + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2020 · Synced Sep 30, 2026, 2:03 AM EDT
Completed Not applicable Interventional Results available

Sub-Sensitivity to Long-Acting Bronchodilators (LABA)

NCT01117116
View directory record Official record
Conditions
Asthma
Interventions
fluticasone propionate and salmeterol, budesonide and formoterol
Drug
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 30, 2026, 2:03 AM EDT
Recruiting Phase 4 Interventional

Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

NCT01225913
View directory record Official record
Conditions
Asthma
Interventions
fluticasone/salmeterol in all asthmatics, budesonide/formoterol or fluticasone/salmeterol in all asthmatics
Drug
Lead sponsor
Gelb, Arthur F., M.D.
Individual
Eligibility
10 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2027
U.S. locations
1
States / cities
Lakewood, California
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Sep 30, 2026, 2:03 AM EDT
Completed Phase 2 Interventional Results available

Personalized Treatment Algorithms for Difficult-to-treat Asthma

NCT04179461
View directory record Official record
Conditions
Asthma in Children
Interventions
Cholecalciferol, antihistamine, Azithromycin, emollient cream, Fluticasone Propionate, Asthma Controller Medication
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 17 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 20, 2021 · Synced Sep 30, 2026, 2:03 AM EDT
Completed Phase 2 Interventional

Single-dose Crossover Study to Evaluate the Early Bronchodilating Effect of FlutiForm HFA pMDI in Adult Subjects With Mild to Moderate Asthma

NCT00734292
View directory record Official record
Conditions
Mild to Moderate Asthma
Interventions
fluticasone propionate, formoterol fumarate, fluticasone propionate, formoterol fumarate
Drug · Other
Lead sponsor
SkyePharma AG
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
8
States / cities
Anaheim, California • Mission Viejo, California • Denver, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Sep 30, 2026, 2:03 AM EDT
Completed Phase 3 Interventional

New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo in Patients With Moderate to Severe Asthma

NCT00393952
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone propionate/Formoterol fumarate 250/10, Placebo, Fluticasone propionate/Formoterol fumarate 100/10, Fluticasone propionate 250, Formoterol fumarate 10
Drug
Lead sponsor
SkyePharma AG
Industry
Eligibility
12 Years and older
Enrollment
557 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
62
States / cities
Pell City, Alabama • Glendale, Arizona • Phoenix, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2011 · Synced Sep 30, 2026, 2:03 AM EDT
Active, not recruiting Phase 2 Interventional

Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma

NCT06676319
View directory record Official record
Conditions
Asthma
Interventions
Lunsekimig, Short-Acting Beta Agonists (SABA), Placebo, Fluticasone/Salmeterol, Budesonide/Formoterol, Budesonide/Albuterol
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 80 Years
Enrollment
556 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
53
States / cities
Saraland, Alabama • Chandler, Arizona • Sun City, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Sep 30, 2026, 2:03 AM EDT
Recruiting No phase listed Observational

Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

NCT00576069
View directory record Official record
Conditions
Asthma
Interventions
budesonide/formoterol, fluticasone/salmeterol, mometasone/formoterol, Prednisone
Drug
Lead sponsor
Gelb, Arthur F., M.D.
Individual
Eligibility
10 Years to 95 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2027
U.S. locations
1
States / cities
Lakewood, California
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Sep 30, 2026, 2:03 AM EDT
Completed Phase 2 Interventional

A Trial to Assess the Pharmacodynamic Response in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01168310
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Fluticasone Propionate/Formoterol Fumarate, Formoterol Fumarate, Placebo
Drug
Lead sponsor
Dey
Industry
Eligibility
40 Days and older
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
23
States / cities
Phoenix, Arizona • Fullerton, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated May 27, 2013 · Synced Sep 30, 2026, 2:03 AM EDT
Recruiting Phase 4 Interventional

Individualizing Treatment for Asthma in Primary Care (Full Study)

NCT07052942
View directory record Official record
Conditions
Asthma, Asthma Attack, Asthma Exacerbations
Interventions
Inhaled corticosteroid (ICS), Azithromycin, Asthma Symptom Monitoring Web-based Application
Drug · Other
Lead sponsor
DARTNet Institute
Government
Eligibility
13 Years to 75 Years
Enrollment
3,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
13
States / cities
Aurora, Colorado • Orlando, Florida • Kansas City, Kansas + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Sep 30, 2026, 2:03 AM EDT
Completed Phase 3 Interventional

Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo, in Patients With Asthma

NCT00393991
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone propionate/formoterol fumarate 100/10, Fluticasone propionate 100, Formoterol fumarate 10, Placebo
Drug
Lead sponsor
SkyePharma AG
Industry
Eligibility
12 Years and older
Enrollment
475 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
47
States / cities
Pell City, Alabama • Scottsdale, Arizona • Cypress, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2011 · Synced Sep 30, 2026, 2:03 AM EDT
Not listed Phase 4 Interventional

Onset of Action of Advair Hydrofluoroalkane (HFA) 115/21 in Comparison to Symbicort Pressurised Metered-Dose Inhalers (pMDI) 160/4.5 Measured by Impulse Oscillometry (IOS)

NCT00867737
View directory record Official record
Conditions
Asthma
Interventions
Advair HFA MDI 115/21, Symbicort 160/4.5 pMDI
Drug
Lead sponsor
Allergy and Asthma Center of El Paso
Other
Eligibility
12 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Mar 24, 2009 · Synced Sep 30, 2026, 2:03 AM EDT
Completed Phase 4 Interventional Results available

Individualizing Treatment for Asthma in Primary Care

NCT06272370
View directory record Official record
Conditions
Asthma, Bronchial Diseases, Respiratory Tract Infections, Lung Diseases, Obstructive, Lung Diseases, Respiratory Hypersensitivity, Immune System Diseases
Interventions
Asthma Symptom Monitoring online tools, Inhaled Steroids, Azithromycin Pill
Other · Drug
Lead sponsor
DARTNet Institute
Government
Eligibility
12 Years to 75 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 20, 2025 · Synced Sep 30, 2026, 2:03 AM EDT
Completed Phase 2 Interventional

A Study Evaluating Systemic Exposure and Pharmacodynamics in Patients With Chronic Obstructive Pulmonary Disease

NCT00774761
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
fluticasone propionate/formoterol fumarate, fluticasone propionate, formoterol fumarate
Drug
Lead sponsor
Dey
Industry
Eligibility
40 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
12
States / cities
San Diego, California • Panama City, Florida • Madisonville, Kentucky + 9 more
Source: ClinicalTrials.gov public record
Updated May 20, 2013 · Synced Sep 30, 2026, 2:03 AM EDT
Terminated Not applicable Interventional Results available

The Effects of Different Long-acting Bronchodilator Medications on Asthma Patients With Different Genetic Variations

NCT00706446
View directory record Official record
Conditions
Asthma
Interventions
tiotropium bromide, Salmeterol, Formoterol, Fluticasone propionate, budesonide
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Sep 30, 2026, 2:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Healthy Volunteers to Evaluate Serum and Urine Levels of the Investigational Product Versus Comparator.

NCT00280358
View directory record Official record
Conditions
Healthy
Interventions
Fluticasone Propionate, Formoterol Fumarate
Drug
Lead sponsor
Dey
Industry
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2005
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 7, 2008 · Synced Sep 30, 2026, 2:03 AM EDT
Completed Phase 1 Interventional

A Phase I Study in Asthma Patients Evaluating the Effect of Doses of FlutiForm™ on the Amount, if Any, of Cortisol Produced by the Adrenal Glands

NCT00657774
View directory record Official record
Conditions
Asthma
Interventions
FlutiForm 250/10 ug, FlutiForm 100/10 ug, Oral Prednisone 10mg, Placebo
Drug
Lead sponsor
SkyePharma AG
Industry
Eligibility
18 Years to 65 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
19
States / cities
Phoenix, Arizona • Anaheim, California • Long Beach, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2008 · Synced Sep 30, 2026, 2:03 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma

NCT02573233
View directory record Official record
Conditions
Asthma
Interventions
Placebo, Dupilumab SAR231893/REGN668, fluticasone propionate and salmeterol, budesonide and formoterol, mometasone furoate and formoterol
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
6
States / cities
Tucson, Arizona • Denver, Colorado • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Sep 30, 2026, 2:03 AM EDT
Completed Phase 2 Interventional

A Dose-Finding Study Evaluating Safety and Efficacy in Patients With Chronic Obstructive Pulmonary Disease

NCT00403286
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Fluticasone Propionate/Formoterol Fumarate, Fluticasone Propionate, Formoterol Fumarate, Fluticasone Propionate/Salmeterol Xinafoate, Placebo
Drug
Lead sponsor
Dey
Industry
Eligibility
40 Years and older
Enrollment
457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
49
States / cities
Birmingham, Alabama • Jasper, Alabama • Phoenix, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2009 · Synced Sep 30, 2026, 2:03 AM EDT
Completed Phase 4 Interventional Results available

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT03478683
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
budesonide/formoterol, albuterol/salbutamol, FF/UMEC/VI, Placebo to match budesonide/formoterol, tiotropium, Placebo to match FF/UMEC/VI, placebo to match tiotropium, ELLIPTA, MDI, HandiHaler
Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
729 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
40
States / cities
Gold River, California • Clearwater, Florida • DeBary, Florida + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2020 · Synced Sep 30, 2026, 2:03 AM EDT
Completed Phase 3 Interventional

Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone & Formoterol Administered Alone in Patients With Asthma

NCT00394199
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone propionate/Formoterol Fumarate 100/10, Fluticasone propionate 100, Formoterol fumarate 10
Drug
Lead sponsor
SkyePharma AG
Industry
Eligibility
12 Years and older
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
29
States / cities
Birmingham, Alabama • Mission Viejo, California • Orange, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2011 · Synced Sep 30, 2026, 2:03 AM EDT
Recruiting Phase 2 Interventional

VENTURI (VENTilation Using Respiratory Imaging)

NCT07282886
View directory record Official record
Conditions
Asthma
Interventions
Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrrolate pMDI, Fluticasone Furoate/Umeclidinium/Vilanterol 100 MCG/1 ACTUATION-62.5 MCG/1 ACTUATION-25 MCG/1 ACTUATION Inhalation Powder
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Sep 30, 2026, 2:03 AM EDT
Completed Phase 2 Interventional Results available

An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma

NCT01854047
View directory record Official record
Conditions
Asthma
Interventions
Dupilumab, placebo, ICS/LABA therapy, Salbutamol/albuterol, Levosalbutamol/levalbuterol
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
776 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
50
States / cities
Fullerton, California • Huntington Beach, California • Los Angeles, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Sep 30, 2026, 2:03 AM EDT
Terminated Phase 4 Interventional Results available

Nebulizer Versus Dry Powdered Inhalers for Chronic Obstructive Pulmonary Disease (COPD)

NCT03219866
View directory record Official record
Conditions
COPD, COPD Exacerbation
Interventions
Nebulizers, Dry Powder Inhaler, Brovana, Pulmicort, Atrovent, Advair Diskus, Spiriva HandiHaler
Device · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
40 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Sep 30, 2026, 2:03 AM EDT